Skip to content
The Policy VaultThe Policy Vault

Joenja (leniolisib)Highmark

Activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)

Initial criteria

  • age ≥ 12 years
  • Patient weighs ≥ 45 kg
  • Diagnosis of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) (ICD-10: D81.82)
  • Confirmed variant in PIK3CD OR PIK3R1 gene
  • Clinical findings of APDS (e.g., lymphoproliferation, lymphadenopathy, splenomegaly, recurrent infections)

Reauthorization criteria

  • Prescriber attests the member is tolerating therapy AND has experienced a therapeutic response defined as disease improvement OR delayed disease progression

Approval duration

12 months